A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
Multiple myeloma is a disease that resides primarily in the bone and has shown to be
sensitive to radiation. Administration of a radiotherapy agent that targets the bone, such as
Holmium-166-DOTMP, in conjunction with melphalan and an autologous stem cell transplant, may
improve the patient's chance of responding to treatment. The purpose of this study is to
determine the amount of Holmium-166-DOTMP that localizes in the bone and in normal organs,
and to evaluate the safety and efficacy of Holmium-166-DOTMP in the treatment of patients
with multiple myeloma.